Drug intelligence / Profile preview

metoprolol tartrate + metoprolol succinate + diltiazem + verapamil

Development stage: Unknown
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This appears to be a combination of four separate cardiovascular medications: metoprolol tartrate (immediate-release beta-blocker), metoprolol succinate (extended-release beta-blocker), diltiazem (calcium channel blocker), and verapamil (calcium channel blocker). This is not a standard combination therapy and would be concerning from a safety perspective as it contains two different forms of the same active ingredient (metoprolol) plus two calcium channel blockers. Taking these medications together would likely cause dangerous additive effects including severe bradycardia, hypotension, and heart block.

Targets

LTCC (Voltage-gated calcium channel (L-type))ADRB1 (β1)

Beyond the preview

Go deeper on metoprolol tartrate + metoprolol succinate + diltiazem + verapamil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol tartrate + metoprolol succinate + diltiazem + verapamil.

Explore the full profile